AIVIS Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 43

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 9

AIVIS General Information

Description

Developer of an artificial intelligence-powered pathology quantification software designed for precision medicine. The company's platform offers tools that deliver rapid, reliable, and robust immunohistochemistry quantification through smart AI-based technology for accurate cancer diagnostics, enabling pathologists, medical researchers, and healthcare professionals to achieve precise and efficient analysis of pathology samples.

Contact Information

Website
www.aivis.kr
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 6th & 8th floor, 238
  • Teheran-ro, Gangnam-gu
  • Seoul
  • South Korea
+82
Primary Industry
Decision/Risk Analysis
Vertical(s)
Artificial Intelligence & Machine Learning, HealthTech, Life Sciences, Oncology
Corporate Office
  • 6th & 8th floor, 238
  • Teheran-ro, Gangnam-gu
  • Seoul
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AIVIS Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 03-Feb-2026 Completed Generating Revenue
6. Accelerator/Incubator 10-Jul-2025 Completed Generating Revenue
5. Early Stage VC (Series A) 18-Dec-2024 Completed Generating Revenue
4. Accelerator/Incubator 16-Dec-2024 Completed Generating Revenue
3. Accelerator/Incubator 21-Dec-2023 Completed Generating Revenue
2. Seed Round 12-Sep-2023 Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view AIVIS’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

AIVIS Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AIVIS Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Aimedbio Corporation Minority
Intops Investment Venture Capital Minority
MYSC PE-Backed Company Minority
Nextrans Venture Capital Minority
Seoul Biohub Accelerator/Incubator
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

AIVIS FAQs

  • When was AIVIS founded?

    AIVIS was founded in 2021.

  • Where is AIVIS headquartered?

    AIVIS is headquartered in Seoul, South Korea.

  • What is the size of AIVIS?

    AIVIS has 43 total employees.

  • What industry is AIVIS in?

    AIVIS’s primary industry is Decision/Risk Analysis.

  • Is AIVIS a private or public company?

    AIVIS is a Private company.

  • What is AIVIS’s current revenue?

    The current revenue for AIVIS is .

  • Who are AIVIS’s investors?

    Aimedbio, Intops Investment, MYSC, Nextrans, and Seoul Biohub are 5 of 9 investors who have invested in AIVIS.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process